These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 28415714)

  • 1. Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.
    Lee CK; Kim SS; Park S; Kim C; Heo SJ; Lim JS; Kim H; Kim HS; Rha SY; Chung HC; Park S; Jung M
    Oncotarget; 2017 May; 8(19):31169-31179. PubMed ID: 28415714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Depth of response predicts the clinical outcome of advanced HER2-positive gastric cancer to trastuzumab-based first-line chemotherapy.
    Kadowaki S; Masuishi T; Eto T; Narita Y; Taniguchi H; Ura T; Ando M; Tajika M; Niwa Y; Yatabe Y; Muro K
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):807-813. PubMed ID: 28821938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Early tumor shrinkage and depth of response in patients with advanced gastric cancer: a retrospective analysis of a randomized phase III study of first-line S-1 plus oxaliplatin vs. S-1 plus cisplatin.
    Nishina T; Azuma M; Nishikawa K; Gotoh M; Bando H; Sugimoto N; Amagai K; Chin K; Niwa Y; Tsuji A; Imamura H; Tsuda M; Yasui H; Fujii H; Yamaguchi K; Yasui H; Hironaka S; Shimada K; Miwa H; Mitome T; Kageyama H; Hyodo I
    Gastric Cancer; 2019 Jan; 22(1):138-146. PubMed ID: 29948386
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Relationship of early tumor shrinkage and depth of response with the prognosis and treatment effect of trastuzumab combined with chemotherapy as first-line treatment in advanced gastric cancer patients with epidermal growth factor receptor 2 positive].
    Zhu N; Chen JQ; Yang MY; Cheng Y; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2020 Oct; 42(10):869-875. PubMed ID: 33113630
    [No Abstract]   [Full Text] [Related]  

  • 5. Poor efficacy response to trastuzumab therapy in advanced gastric cancer with homogeneous HER2 positive and non-intestinal type.
    Xu C; Liu Y; Jiang D; Li Q; Ge X; Zhang Y; Huang J; Su J; Ji Y; Hou J; Lu S; Hou Y; Liu T
    Oncotarget; 2017 May; 8(20):33185-33196. PubMed ID: 28388541
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Associations between early tumor shrinkage and depth of response and clinical outcomes in patients treated with 1st-line chemotherapy for advanced gastric cancer.
    Osumi H; Takahari D; Shinozaki E; Chin K; Ogura M; Wakatsuki T; Ichimura T; Nakayama I; Matsushima T; Yamaguchi K
    Gastric Cancer; 2018 Mar; 21(2):267-275. PubMed ID: 28584889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Depth of Response and Early Tumor Shrinkage for Predicting Clinical Outcomes in HER2-Positive Metastatic Breast Cancer Treated with Trastuzumab.
    Che YQ; Zhang Y; Ou KP; Wang D; Shen D; Liu HY; Luo Y
    Cancer Manag Res; 2020; 12():8527-8534. PubMed ID: 32982445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A prospective observational study on the optimal maintenance strategy in HER2-positive advanced gastric cancer treated with trastuzumab-based therapy.
    Li Q; Lv M; Jiang H; Wang Y; Yu S; Li W; Yu Y; Liu T
    J Cancer Res Clin Oncol; 2020 Jan; 146(1):287-295. PubMed ID: 31667572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival analysis based on human epidermal growth factor 2 status in stage II-III gastric cancer.
    Cho JH; Lim JY; Cho JY
    World J Gastroenterol; 2017 Nov; 23(41):7407-7414. PubMed ID: 29151694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of Chemotherapy with Trastuzumab in Advanced Gastric Cancer].
    Kawada J; Nakatsuka R; Motoori M; Miyazaki S; Danno K; Kubota M; Matsuda C; Nishikawa K; Fujitani K; Iwase K; Tsujinaka T; Tanaka Y
    Gan To Kagaku Ryoho; 2015 Nov; 42(12):2091-3. PubMed ID: 26805274
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Tumor Shrinkage and Depth of Response as Predictors of Favorable Treatment Outcomes in Patients with Metastatic Colorectal Cancer Treated with FOLFOX Plus Cetuximab (JACCRO CC-05).
    Tsuji A; Sunakawa Y; Ichikawa W; Nakamura M; Kochi M; Denda T; Yamaguchi T; Shimada K; Takagane A; Tani S; Kotaka M; Kuramochi H; Furushima K; Koike J; Yonemura Y; Takeuchi M; Fujii M; Nakajima T
    Target Oncol; 2016 Dec; 11(6):799-806. PubMed ID: 27306648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.
    Piessevaux H; Buyse M; Schlichting M; Van Cutsem E; Bokemeyer C; Heeger S; Tejpar S
    J Clin Oncol; 2013 Oct; 31(30):3764-75. PubMed ID: 24043732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Roles of HER2 Gene Amplification and Neutrophil-to-Lymphocyte Ratio on Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab-Based Chemotherapy.
    Park JH; Yeo JH; Kim YS; Park I; Ahn HK; Shin DB; Lee WK; Yang JY; Kim HS; Sym SJ
    Am J Clin Oncol; 2021 Jun; 44(6):232-238. PubMed ID: 33710139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
    van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
    Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term cardiovascular outcomes and overall survival of early-stage breast cancer patients with early discontinuation of trastuzumab: a population-based study.
    Gong IY; Verma S; Yan AT; Ko DT; Earle CC; Tomlinson GA; Trudeau ME; Krahn MD; Krzyzanowska MK; Brezden-Masley CB; Gavura S; Peacock S; Chan KK
    Breast Cancer Res Treat; 2016 Jun; 157(3):535-44. PubMed ID: 27271767
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prealbumin-to-Globulin Ratio Can Predict the Chemotherapy Outcomes and Prognosis of Patients with Gastric Cancer Receiving First-Line Chemotherapy.
    Wang Z; Zhang L; Wang J; Wang Y; Dong Q; Piao H; Wang Q; Zhang J
    J Immunol Res; 2020; 2020():6813176. PubMed ID: 32832571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early tumor shrinkage as a predictor of favorable outcomes in patients with advanced pancreatic cancer treated with FOLFIRINOX.
    Kaga Y; Sunakawa Y; Kubota Y; Tagawa T; Yamamoto T; Ikusue T; Uto Y; Miyashita K; Toshima H; Kobayashi K; Hisamatsu A; Ichikawa W; Sekikawa T; Shimada K; Sasaki Y
    Oncotarget; 2016 Oct; 7(41):67314-67320. PubMed ID: 27634903
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study.
    Li Q; Li H; Jiang H; Feng Y; Cui Y; Wang Y; Ji Y; Yu Y; Li W; Xu C; Yu S; Zhuang R; Liu T
    Clin Transl Oncol; 2018 Jun; 20(6):695-702. PubMed ID: 29168107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elevated Neutrophil-to-Lymphocyte Ratio Predicts Survival in Patients with Advanced Gastric Cancer Treated with Trastuzumab Combination Chemotherapy.
    Hwang GY; Baek DW; Cho HJ; Lee SJ; Chae YS; Kang BW; Lee IH; Kim JG; Seo AN; Bae HI; Park KB; Park JY; Kwon OK; Lee SS; Chung HY
    Anticancer Res; 2018 May; 38(5):3151-3156. PubMed ID: 29715156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early tumor shrinkage and depth of response in patients with metastatic esophageal cancer treated with 2-weekly docetaxel combined with cisplatin plus fluorouracil: an exploratory analysis of the JCOG0807.
    Ura T; Hironaka S; Tsubosa Y; Mizusawa J; Kato K; Tsushima T; Fushiki K; Chin K; Tomori A; Okuno T; Matsushita H; Kojima T; Doki Y; Kusaba H; Fujitani K; Seki S; Kitagawa Y
    Esophagus; 2023 Apr; 20(2):272-280. PubMed ID: 36427158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.